Article
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2017
Beaver Julia A, Theoret Marc R, Mushti Sirisha, He Kun, Libeg Meredith, Goldberg Kirsten, Sridhara Rajeshwari, McKee Amy E, Keegan Patricia, Pazdur Richard
Abstract excerpt
On November 23, 2015, the FDA approved nivolumab (OPDIVO; Bristol-Myers Squibb) as a single agent for the first-line treatment of patients with BRAFV600 wild-type, unresectable or metastatic melanoma. An international, double-blind, randomized (1:1) trial conducted outside of the United States allocated 418 patients to receive nivolumab 3 mg/kg intravenously every 2 weeks (n = 210) or dacarbazine 1,000 mg/m2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.